Margaret Bradbury has over 20 years of experience in the biotech and pharmaceutical industries, leading successful projects and teams in pharmacology, pharmacokinetics and toxicology. Margaret serves as the Vice President of Nonclinical Development and Research at Alterity Therapeutics. Prior to joining Alterity she was a Senior Director at Teva Pharmaceuticals and an Executive Director at Auspex Pharmaceuticals.  During her tenure she guided the nonclinical studies leading to FDA’s approval of Austedo®, the first approved deuterium-substituted small molecule drug.  Prior to Teva, Margaret was Associate Director of Neuroscience Research at Neurocrine Biosciences, and led various projects at Merck Research Laboratories.